Valuation: Genix Pharmaceuticals Corporation

Market Cap 918K 652K 573K 532K 490K 62.94M 936K 6.36M 2.48M 30.83M 2.45M 2.4M 107M P/E 2024
-40.5x
P/E 2025 -5.33x
Enterprise Value 1.92M 1.36M 1.2M 1.11M 1.02M 131M 1.95M 13.28M 5.18M 64.37M 5.11M 5M 223M EV / Sales 2024
929,496,174x
EV / Sales 2025 -
Free-Float
53.08%
Yield 2024 *
-
Yield 2025 -
3 months-25.00%
6 months-40.00%
Current year-40.00%
1 month 0.02
Extreme 0.015
0.02
Current year 0.02
Extreme 0.015
0.02
1 year 0.02
Extreme 0.015
0.04
3 years 0.02
Extreme 0.015
0.09
5 years 0.02
Extreme 0.015
0.2
10 years 0.01
Extreme 0.01
0.3
Manager TitleAgeSince
Chief Executive Officer 57 2018-08-02
President - 2021-05-20
Director of Finance/CFO - 2020-12-13
Director TitleAgeSince
Director/Board Member 57 2018-08-02
Director/Board Member 76 2019-03-10
Director/Board Member 44 2019-09-04
Date Insider Type Main position Quantity % Market Cap.
9/9/25 Option

Chief Executive Officer

1,000,000 1.6885%
9/9/25 Option

Chief Executive Officer

1,000,000 1.6885%
9/9/25 Other

Chairman

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-50.00%-75.00% 652K
+0.57%+0.13%+16.45%+78.10% 48.31B
-0.50%-0.41%+67.13%+107.90% 35.33B
-1.56%-3.13%-4.88%+32.80% 11.85B
-1.11%-3.73%+16.41%+81.64% 11.64B
-0.37%-0.19%+36.48%+136.73% 8.99B
-0.27%+0.42%+51.66%-6.22% 6.93B
-0.77%-3.00%+13.55%+32.01% 6.72B
+0.24%-4.02%+2.19%+192.78% 6.43B
+1.60%-9.55%-30.77%+8.47% 5.66B
Average -0.22%-1.56%+11.82%+58.92% 14.19B
Weighted average by Cap. -0.15%-0.93%+27.60%+81.86%

Financials

2024 2025
Net sales 0 0 0 0 0 0.28 0 0.03 0.01 0.14 0.01 0.01 0.47 -
Net income -73.2K -51.93K -45.68K -42.44K -39.04K -5.02M -74.6K -507K -198K -2.46M -195K -191K -8.51M -335K -238K -209K -194K -179K -22.96M -341K -2.32M -904K -11.25M -893K -874K -38.97M
Net Debt 804K 571K 502K 466K 429K 55.11M 820K 5.57M 2.17M 26.99M 2.14M 2.1M 93.54M 999K 709K 624K 579K 533K 68.48M 1.02M 6.92M 2.7M 33.54M 2.66M 2.61M 116M
Logo Genix Pharmaceuticals Corporation
Genix Pharmaceuticals Corporation is a Canadian ophthalmic drugs company. The Company is a formulator, manufacturer, licensor and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its operations consist primarily of the research, development, manufacture, in-licensing and sales of novel and healthcare products, focusing on proprietary over the counter (OTC) nutraceuticals and generic pharmaceuticals. The Company has been marketing and selling other nutraceuticals and some pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels and spirulina powder. Its products include Ketorolac 0.5% Eye Drops, Timolol 0.5% Eye Drops, Diclofenac 0.1% Eye Drops, Moxifloxacin Hydrochloride 0.5% Eye Drops, Prednisolone Acetate 1% Eye Drops, Olopatadine 0.1% Eye Drops, and others.
Employees
4,000
  1. Stock Market
  2. Stocks
  3. GENX Stock